Who
Kenneth C. Frazier
Director
Company insider
Files Form 4 as: Director, Eikon Therapeutics; Executive Chair, Merck & Company; Director, Exxon Mobil; Exec. VP & President, GHH, Merck Sharp & Dohme.
In numbers
- Trades disclosed
- 291
- Buys
- 2
- Sells
- 41
- Bought
- $5.0M
- Sold
- $460.2M
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 15 Feb 2006
- Last trade
- 2 Mar 2026
- Last filed
- 4 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Mar 2026filed 4 Mar 2026 | EIKN Eikon Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,873 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | EIKN Eikon Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,873 at $0.00 | filing |
| 4 Feb 2026filed 6 Feb 2026 | EIKN Eikon TherapeuticsBiotechnology | SEC FORM 4 Bought | $2.0M111,111 at $18.00 | filing |
| 4 Feb 2026filed 6 Feb 2026 | EIKN Eikon TherapeuticsBiotechnology | SEC FORM 4 Bought | $2.0M111,111 at $18.00 | filing |
| 7 Nov 2022filed 8 Nov 2022 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —235,769 at $0.00 | filing |
| 7 Nov 2022filed 8 Nov 2022 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Code M | —235,769 at $0.00 | filing |
| 7 Nov 2022filed 8 Nov 2022 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Sold | $2.5M24,914 at $98.45 | filing |
| 7 Nov 2022filed 8 Nov 2022 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Sold | $12.5M126,134 at $99.42 | filing |
| 7 Nov 2022filed 8 Nov 2022 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Sold | $8.5M84,721 at $100.07 | filing |
| 4 Nov 2022filed 7 Nov 2022 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —235,000 at $0.00 | filing |
| 4 Nov 2022filed 7 Nov 2022 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Code M | —235,000 at $0.00 | filing |
| 4 Nov 2022filed 7 Nov 2022 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Sold | $19.7M200,190 at $98.53 | filing |
| 4 Nov 2022filed 7 Nov 2022 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Sold | $3.4M34,810 at $99.08 | filing |
| 3 Nov 2022filed 7 Nov 2022 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —235,000 at $0.00 | filing |
| 3 Nov 2022filed 7 Nov 2022 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Code M | —235,000 at $0.00 | filing |
| 3 Nov 2022filed 7 Nov 2022 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Sold | $21.2M214,617 at $98.68 | filing |
| 3 Nov 2022filed 7 Nov 2022 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Sold | $2.0M20,383 at $99.09 | filing |
| 2 Nov 2022filed 3 Nov 2022 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —165,828 at $0.00 | filing |
| 2 Nov 2022filed 3 Nov 2022 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —134,172 at $0.00 | filing |
| 2 Nov 2022filed 3 Nov 2022 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Code M | —165,828 at $0.00 | filing |
News
Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology CongressEIKN · manilatimes.net · 19 Oct 2026Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate CancerEIKN · manilatimes.net · 15 Oct 2026
0 headlines in the last 90 days name Kenneth C. Frazier; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.